AI-Driven Pharmacovigilance for Neuropsychiatric Drugs: FDA Prospects and Pitfalls

AI's Emerging Role in FDA Pharmacovigilance for Neuropsychiatric Drugs

Artificial intelligence (AI) is being explored as a tool to enhance the U.S. Food and Drug Administration's (FDA) post-marketing surveillance of neuropsychiatric medications, including psychedelic-adjacent agents such as esketamine. The FDA currently relies on systems like the Adverse Event Reporting System (FAERS), MedWatch, the Sentinel System, and Risk Evaluation and Mitigation Strategies (REMS) to detect safety signals after drugs reach the market. However, these systems struggle to capture the full scope of adverse effects—especially those that are subjective, delayed, or confounded by underlying psychiatric illness. AI-driven methods, particularly natural language processing (NLP) and large language models (LLMs), are now being piloted to structure and prioritize safety signals from both structured and unstructured data sources.

Mechanisms: How AI Can Enhance Adverse Event Detection

AI tools can process vast amounts of real-world data, including free-text clinical notes, electronic health records (EHRs), and spontaneous reports, to identify patterns that may signal adverse drug reactions. For example, NLP algorithms have demonstrated good accuracy in extracting psychiatric adverse events from narrative records, which often go unreported in structured fields. LLMs are being tested to summarize and categorize complex adverse event narratives, potentially surfacing signals that traditional systems miss. This is particularly relevant for neuropsychiatric drugs, where effects like dissociation or suicidal ideation (as seen with esketamine) are difficult to distinguish from disease symptoms and may be underreported due to stigma or diagnostic uncertainty.

Despite these advances, most AI applications in pharmacovigilance remain retrospective proofs of concept. They are not yet validated for live regulatory workflows, and their ability to generalize across diverse patient populations is unproven. Notably, the review highlights that AI models trained on biased or incomplete data can perpetuate existing inequities in adverse event detection, a risk that is magnified in psychiatric populations historically subject to underreporting and misdiagnosis.

Policy and Research Implications: Integration, Oversight, and Validation

The integration of AI into FDA pharmacovigilance could reshape how safety signals are detected, prioritized, and acted upon for neuropsychiatric and psychedelic therapies. However, regulatory decisions must remain clinician- and regulator-led. AI should be viewed as a tool for signal amplification and triage, not as a replacement for expert judgment. The review underscores the need for prospective evaluation of AI tools within live pharmacovigilance workflows—an area where current research is sparse. Linking FAERS data with EHRs and insurance claims could provide a more comprehensive view of adverse events, but privacy, interoperability, and data quality remain hurdles.

One non-obvious implication is that AI-enabled pharmacovigilance could shift the industry's approach to post-marketing commitments and REMS for psychedelic therapies. If AI tools reliably flag emerging risks earlier, sponsors may face greater scrutiny or more frequent updates to risk mitigation strategies, potentially increasing the operational burden for developers and marketers of novel neuropsychiatric drugs.

Risks, Limitations, and Unknowns

AI-driven pharmacovigilance is not without significant risks. Models may amplify notoriety bias, where widely publicized adverse events (such as dissociation with esketamine) are overrepresented, skewing safety profiles. Solicited reporting under REMS can further inflate disproportionality signals, complicating causality assessment. Long-latency effects—such as tardive dyskinesia or metabolic changes from antipsychotics—often fall outside the observation windows of both premarket trials and spontaneous reporting systems, and AI models may struggle to detect these without longitudinal, high-quality data.

Moreover, the subjective nature of many neuropsychiatric adverse events, coupled with stigma and diagnostic overshadowing, means that even advanced AI may miss critical safety signals unless reporting barriers are addressed. The review calls for efforts to reduce stigma and improve point-of-care reporting tools, but the effectiveness of these interventions remains to be demonstrated.

Looking Forward: Prospects for Psychedelic and Neuropsychiatric Drug Safety

Prospective validation of AI tools in real-world pharmacovigilance is a top priority for regulators and industry alike. As psychedelic therapies move through the FDA pipeline and into broader clinical use, robust and equitable safety surveillance will be essential. AI offers the potential to accelerate signal detection and support more responsive regulatory action, but only if its limitations are transparently addressed and its outputs are integrated with clinical expertise.

For stakeholders, the next phase will require collaboration across regulators, industry sponsors, clinicians, and patient groups to ensure that AI augments—rather than replaces—human oversight in drug safety. As the field evolves, the balance between innovation and caution will shape both regulatory policy and public trust in new neuropsychiatric therapies.

How we research: This article was researched and written by Dr. Alex M. Carter, PhD (neuropharmacology, regulatory science), and reviewed by Dr. Lisa Tran, MD, on 2026-10-15. Sources include the original OpenAlex review (link), FDA documentation, and primary regulatory filings.